[go: up one dir, main page]

ZA958028B - Compositions and methods for treatig mast-cell mediated conditions - Google Patents

Compositions and methods for treatig mast-cell mediated conditions

Info

Publication number
ZA958028B
ZA958028B ZA958028A ZA958028A ZA958028B ZA 958028 B ZA958028 B ZA 958028B ZA 958028 A ZA958028 A ZA 958028A ZA 958028 A ZA958028 A ZA 958028A ZA 958028 B ZA958028 B ZA 958028B
Authority
ZA
South Africa
Prior art keywords
treatig
mast
compositions
methods
cell mediated
Prior art date
Application number
ZA958028A
Other languages
English (en)
Inventor
Ken D Rice
Jefferey M Dener
Anthony R Gangloff
Elain Y Kuo
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of ZA958028B publication Critical patent/ZA958028B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/32Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/18Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA958028A 1994-09-23 1995-09-22 Compositions and methods for treatig mast-cell mediated conditions ZA958028B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31226994A 1994-09-23 1994-09-23

Publications (1)

Publication Number Publication Date
ZA958028B true ZA958028B (en) 1996-04-18

Family

ID=23210670

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958028A ZA958028B (en) 1994-09-23 1995-09-22 Compositions and methods for treatig mast-cell mediated conditions

Country Status (25)

Country Link
US (2) US6022969A (xx)
EP (1) EP0782571A1 (xx)
JP (1) JPH10506390A (xx)
KR (1) KR970706267A (xx)
CN (1) CN1160398A (xx)
AU (1) AU694275B2 (xx)
CA (1) CA2200561A1 (xx)
CZ (1) CZ87097A3 (xx)
EE (1) EE03525B1 (xx)
FI (1) FI971171A7 (xx)
HR (1) HRP950499B1 (xx)
HU (1) HUT77770A (xx)
IL (1) IL115405A (xx)
LT (1) LT4234B (xx)
LV (1) LV11865B (xx)
MX (1) MX9702125A (xx)
NO (1) NO309605B1 (xx)
NZ (1) NZ294392A (xx)
PL (1) PL183552B1 (xx)
RU (1) RU2159229C2 (xx)
SI (1) SI9520101A (xx)
SK (1) SK37997A3 (xx)
TW (1) TW442478B (xx)
WO (1) WO1996009297A1 (xx)
ZA (1) ZA958028B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934293A1 (en) * 1996-07-30 1999-08-11 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity
US5968782A (en) * 1996-12-04 1999-10-19 Brigham And Womens's Hospital, Inc. Mast cell protease that cleaves fibrinogen
US5955431A (en) * 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
WO1999012918A1 (en) * 1997-09-05 1999-03-18 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitor
WO1999024407A1 (en) * 1997-11-10 1999-05-20 Array Biopharma, Inc. Compounds which inhibit tryptase activity
US6221914B1 (en) * 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO1999040083A2 (de) * 1998-02-06 1999-08-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Bifunktionelle tryptase-inhibitoren
JP2002502845A (ja) 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
EP1115731A2 (de) * 1998-09-04 2001-07-18 Byk Gulden Lomberg Chemische Fabrik GmbH Neue pyranosen
US6362216B1 (en) 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
CA2381919A1 (en) * 1999-08-10 2001-02-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tryptase inhibitors
DE19940389A1 (de) * 1999-08-25 2001-03-01 Wilex Biotechnology Gmbh Selektive Inhibitoren des Urokinase-Plasminogen Aktivators
WO2001019809A1 (en) * 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2001036386A1 (en) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Diabetic remedy containing dipiperazine derivative
ATE268322T1 (de) 1999-12-20 2004-06-15 Altana Pharma Ag Inhibitoren der tryptase
CA2392121A1 (en) * 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
WO2001052883A1 (en) * 2000-01-20 2001-07-26 Amgen Inc. Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
ATE273302T1 (de) 2001-01-31 2004-08-15 Altana Pharma Ag Diazocinderivate und deren verwendung als tryptase inhibitoren
EP1363874B1 (en) 2001-02-21 2007-06-06 ALTANA Pharma AG Tryptase inhibitors
DE60217076T2 (de) 2001-02-21 2007-06-21 Altana Pharma Ag Tryptaseinhibitoren
JP2004525926A (ja) * 2001-03-15 2004-08-26 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼ阻害剤
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE60216920T2 (de) 2001-06-19 2007-11-15 Nycomed Gmbh Tryptase-inhibitoren
AU2002352382A1 (en) * 2001-12-13 2003-06-23 Kowa Company Ltd Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TW200524849A (en) * 2003-07-02 2005-08-01 Hoffmann La Roche Hydroxyalkylamide derivatives
RU2276973C2 (ru) * 2004-01-22 2006-05-27 Общество с ограниченной ответственностью "Лечебно-диагностическая фирма "Медик" Противовоспалительная мазь с гиполипидемическим эффектом
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TWI414527B (zh) * 2010-10-06 2013-11-11 Ind Tech Res Inst 異山梨糖醇衍生物及包含該衍生物之液晶顯示器
CN102453037B (zh) * 2010-10-25 2014-06-25 财团法人工业技术研究院 异山梨糖醇衍生物及包含该衍生物的液晶显示器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4746737A (en) * 1985-07-26 1988-05-24 Kowa Co., Ltd. Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
CZ289930B6 (cs) * 1993-03-12 2002-04-17 Axys Pharmaceuticals, Inc. Arylové a heteroarylové peptidové deriváty a farmaceutické prostředky je obsahující
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
US5656660A (en) * 1994-06-01 1997-08-12 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions

Also Published As

Publication number Publication date
NZ294392A (en) 1999-05-28
CZ87097A3 (en) 1997-11-12
EE9700089A (et) 1997-10-15
US6211228B1 (en) 2001-04-03
KR970706267A (ko) 1997-11-03
PL319587A1 (en) 1997-08-18
WO1996009297A1 (en) 1996-03-28
FI971171A0 (fi) 1997-03-20
HUT77770A (hu) 1998-08-28
LV11865B (en) 1998-01-20
LT97065A (en) 1997-08-25
FI971171L (fi) 1997-03-20
LV11865A (lv) 1997-10-20
US6022969A (en) 2000-02-08
HRP950499B1 (en) 2003-04-30
CA2200561A1 (en) 1996-03-28
PL183552B1 (pl) 2002-06-28
NO971305L (no) 1997-05-06
JPH10506390A (ja) 1998-06-23
SK37997A3 (en) 1998-12-02
IL115405A0 (en) 1995-12-31
NO971305D0 (no) 1997-03-20
LT4234B (en) 1997-10-27
SI9520101A (en) 1997-12-31
NO309605B1 (no) 2001-02-26
EP0782571A1 (en) 1997-07-09
FI971171A7 (fi) 1997-03-20
IL115405A (en) 2002-07-25
TW442478B (en) 2001-06-23
AU3718095A (en) 1996-04-09
AU694275B2 (en) 1998-07-16
RU2159229C2 (ru) 2000-11-20
EE03525B1 (et) 2001-10-15
CN1160398A (zh) 1997-09-24
HRP950499A2 (en) 1997-08-31
MX9702125A (es) 1998-04-30

Similar Documents

Publication Publication Date Title
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
HUP9904697A3 (en) Methods and compositions for immunomodulation
GB9616411D0 (en) Shampoo compositions and method
GB9615089D0 (en) Esters and compositions comprising them
GB2348808B (en) Methods and compositions for desensitisation
AU2113295A (en) Novel compositions and methods for water treatment
ZA982188B (en) Compositions and methods for reducing ocular hyper-tension
PL327659A1 (en) Disinfecting compositions and surface disinfecting methods
PL332415A1 (en) Ore cleaning compositions and methods
ZA989399B (en) Method and composition
EP1056456A4 (en) COMPOSITIONS AND METHODS OF USING R-LANSOPRAZOLE
ZA9710419B (en) Compositions and methods for regulating apoptosis
ZA95701B (en) Rivets-nails and methods for their implementation
PL331423A1 (en) Muporocin and chlorohexidrin containing compositions
GB9624501D0 (en) Insecticial compositions and method
ZA959388B (en) Compositions comprising carbazoles and cyclodextrins
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
GB2318356B (en) Composition and method
GB9508546D0 (en) Method and composition
GB9414888D0 (en) Method and composition
GB9419087D0 (en) Method and composition
IL113444A0 (en) Compositions and methods for treating leukemia
GB9617346D0 (en) Therapeutic methods and compositions for use therein
ZA955409B (en) Keratolytic-wound healing compositions and methods for preparing and using same
GB9601656D0 (en) Novel composition and method